What the trial was testing
The TRAILBLAZER-ALZ 2 enrolled 1,736 patients with alzheimer's disease. The study was sponsored by Eli Lilly and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was a large trial designed to confirm whether the treatment works well enough for wider use. Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
35% slower decline — with the largest benefit in people caught soonest.
JAMA · 2023 · NCT04437511
These findings — that in cognitive and daily function for people with early Alzheimer's, especially those caught soonest — were published in the JAMA and represent the headline result of the study.
Researchers tracked outcomes across 1,736 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with alzheimer's disease, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
Donanemab (Kisunla) is FDA-approved and available now. Treatment can stop once amyloid is cleared from the brain, which often happens within 12 to 18 months. Brain swelling and small bleeds are real risks, so most centers screen for the APOE4 gene before starting. Ask a neurologist about eligibility.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open alzheimer's disease trials
Neuroimaging in Healthy Aging and Senile Dementia (HASD_IND)
To identify factors that signal the transition from asymptomatic (preclinical) to symptomatic Alzheimer disease (AD).
Establishment of the Chinese Preclinical Alzheimer's Disease Study With Multiple Neuroimaging
The goal of this observational study is to investigate neuroimage and biomarkers in the Alzheimer's continuum in Chinese population. We aimed to: * To reveal the progress of AD by multiple neuroimage and biomarkers; * To reveal the longitudinal change of biomarkers and cognition of AD in Chinese population; * To investigate the interaction of markers between body and brain; * To set up new markers by neuroimage.